https://www.selleckchem.com/products/ABT-263.html
80[95%CI, 0.69-0.92], P = 0.001), HHF (HR, 0.67[95%CI, 0.60-0.76], P 0.00001), and all-cause mortality (HR, 0.74[95%CI, 0.64-0.86], P 0.0001). Moreover, patients with T2DM and HF may benefit more from the treatment than those with T2DM/HF. The long-term use of SGLT-2 inhibitors can help reduce the risk of mortality and HHF in patients with T2DM and HF. PROSPERO [https//www.crd.york.ac.uk/prospero/di....splay_record.php?ID= identifier [CRD42021233156]. PROSPERO [https//www.crd.york.ac.uk/prospero/display_record.php?
Like
Comment
Share
